GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Cash, Cash Equivalents, Marketable Securities

BRAIN Biotech AG (XTER:BNN) Cash, Cash Equivalents, Marketable Securities : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Cash, Cash Equivalents, Marketable Securities?

BRAIN Biotech AG's quarterly cash, cash equivalents, marketable securities increased from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€10.35 Mil) but then stayed the same from Mar. 2024 (€10.35 Mil) to Jun. 2024 (€0.00 Mil).

BRAIN Biotech AG's annual cash, cash equivalents, marketable securities declined from Sep. 2021 (€24.65 Mil) to Sep. 2022 (€8.81 Mil) and declined from Sep. 2022 (€8.81 Mil) to Sep. 2023 (€5.41 Mil).


BRAIN Biotech AG Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for BRAIN Biotech AG's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Cash, Cash Equivalents, Marketable Securities Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only 15.22 19.05 24.65 8.81 5.41

BRAIN Biotech AG Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.41 - 10.35 -

BRAIN Biotech AG Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


BRAIN Biotech AG  (XTER:BNN) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


BRAIN Biotech AG Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG Headlines

No Headlines